tiprankstipranks
Lumos Pharma (LUMO)
NASDAQ:LUMO
US Market

Lumos Pharma (LUMO) Income Statement

332 Followers

Lumos Pharma Income Statement

Last quarter (Q1 2024), Lumos Pharma's total revenue was $165.00K, a decrease of -67.77% from the same quarter last year. In Q1, Lumos Pharma's net income was $-10.44M. See Lumos Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 1.39M$ 2.05M$ 1.52M$ 220.00K$ 168.00K$ 0.00
Cost of Revenue
------
Gross Profit
$ 1.39M$ 2.05M$ 1.52M$ 230.00K--
Operating Expense
$ 21.41M$ 38.66M$ 33.56M$ -31.58M$ 26.47M$ 9.82M
Operating Income
$ -37.47M$ -36.61M$ -32.04M$ -31.35M$ -26.30M$ -9.82M
Net Non Operating Interest Income Expense
$ 1.73M$ 1.87M$ 874.00K$ 12.00K$ 200.00K$ 74.00K
Other Income Expense
$ -692.00K$ -683.00K$ -91.00K$ -269.00K$ 6.47M$ 37.00K
Pretax Income
$ -35.05M$ -34.06M$ -31.07M$ -31.07M$ -19.64M$ -9.71M
Tax Provision
$ -29.00K$ -29.00K$ -13.00K$ -636.00K$ -13.97M$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -35.02M$ -34.03M$ -31.06M$ -30.43M$ -6.31M$ -12.74M
Basic EPS
$ -4.31$ -4.18$ -3.71$ -3.65$ -0.93$ -10.35
Diluted EPS
$ -4.31$ -4.18$ -3.71$ -3.65$ -0.93$ -10.35
Basic Average Shares
$ 32.49M$ 8.15M$ 8.37M$ 8.33M$ 6.78M$ 4.14M
Diluted Average Shares
$ 32.49M$ 8.15M$ 8.37M$ 8.33M$ 6.78M$ 4.14M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 21.41M$ 38.66M$ 33.56M$ -31.58M$ 26.47M$ 9.82M
Net Income From Continuing And Discontinued Operation
$ -35.02M$ -34.03M$ -31.06M$ -30.43M$ -5.66M$ -9.71M
Normalized Income
$ -25.88M-$ -31.09M-$ -5.66M$ -9.71M
Interest Expense
-----$ 50.00K
EBIT
$ -35.68M$ -36.61M$ -31.07M$ -31.07M$ -26.30M$ -9.82M
EBITDA
$ -35.65M$ -36.57M$ -31.03M$ -30.85M$ -25.72M$ -9.78M
Currency in USD

Lumos Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis